Prevention is better than cure: The case for clinical trials of therapeutic cancer vaccines in the prophylactic setting

Molecular Interventions

Volumn 10, Issue 4, 2010, Pages 197-203

  Gray, Andrew ^a   Yan, Lisa ^a   Kast, W Martin ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROVENGE;

ANTIGEN PRESENTING CELL; AUTOIMMUNITY; BREAST CANCER; CANCER GRADING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REGULATORY T LYMPHOCYTE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; TREATMENT OUTCOME;

EID: 77956017426     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.10.4.2     Document Type: Review

References (20)

1. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, and Frohlich MW (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670-3679. This article reported the results of the phase III clinical trials of sipuleucel-T, the first therapeutic cancer vaccine approved by the FDA.
2. Gray A, Raff AB, Chiriva-Internati M, Chen SY, and Kast WM (2008) A paradigm shift in therapeutic vaccination of cancer patients: The need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev 222: 316-327. (Pubitemid 351430367)
3. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, and Harlin H (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213:131-145. (Pubitemid 44401498)
4. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274. The reviews cited as references 3 and 4 provide excellent summaries of tumor immune escape via the development of intratumoral immunosuppressive networks.
5. Klebanoff CA, Gattinoni L, and Restifo NP (2006) CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211:214-224. (Pubitemid 43882974)
6. Finn OJ (2003) Premalignant lesions as targets for cancer vaccines. J Exp Med 198:1623-1626.
7. Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, and Tuohy VK (2010) An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med 16:799-803. In this seminal paper, the authors demonstrate that complete protection from breast cancer development can be achieved in mice that are prophylactically vaccinated against the tumor-associated autoantigen α-lactalbumin.
8. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, and Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578-10582.
9. Lohrisch C and Piccart M (2001) HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2:129-135. (Pubitemid 32771564)
10. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, and Greenberg NM (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55:219-237. (Pubitemid 36532401)
11. Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, and Kast WM (2008) Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of auto-immunity. Cancer Res 68:861-869. In this study, long-term protection from prostate cancer was achieved when mice with precancerous prostate lesions were vaccinated against the tumor-associated antigen PSCA.
12. Gray A, de la Luz Garcia-Hernandez M, van West M, Kanodia S, Hubby B, and Kast WM (2009) Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 27 Suppl 6:G52-G59.
13. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin- Boes G, Houghton J, Locker GY et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62. (Pubitemid 40082147)
14. Thompson IM, Tangen CM, Klein EA, and Lippman SM (2005) Phase III prostate cancer prevention trials: are the costs justified? J Clin Oncol 23:8161-8164. (Pubitemid 46211549)
15. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224. This article reported the initial findings of the Prostate Cancer Prevention Trial, demonstrating not only that finasteride can lower the incidence of prostate cancer but also the feasibility of large scale, long-term cancer prevention clinical trials. Data obtained from the PCPT continued to be presented in follow-up papers for years after the publication of this initial report.
16. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, and Klein EA (2009) Chemoprevention of prostate cancer. J Urol 182:499-507.
17. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M et al. (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75-89. (Pubitemid 46535708)
18. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R et al. (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099-1105. This article reports the findings of a phase II clinical trial of PROSTVAC-VF, a promising candidate to be the first FDA-approved off-the-shelf therapeutic cancer vaccine.
19. Garcia-Hernandez Mde L, Gray A, Hubby B, and Kast WM (2007) In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 67:1344-1351.
20. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, and Lotan Y (2006) The cost of prostate cancer chemoprevention: A decision analysis model. Cancer Epidemiol Biomarkers Prev 15:1485-1489.